Rituximab for the treatment of myasthenia gravis a review of clinical effectiveness, cost-effectiveness, and guidelines
The purpose of this report is to review the clinical effectiveness and cost-effectiveness of rituximab therapy for the treatment of myasthenia gravis (MG). Additionally, this report aims to review the evidence-based guidelines regarding the use of rituximab for the treatment of MG. This report updat...
Main Authors: | , |
---|---|
Corporate Author: | |
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
CADTH
August 14, 2018, 2018
|
Edition: | Version 1.0 |
Series: | CADTH rapid response report: summary with critical appraisal
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The purpose of this report is to review the clinical effectiveness and cost-effectiveness of rituximab therapy for the treatment of myasthenia gravis (MG). Additionally, this report aims to review the evidence-based guidelines regarding the use of rituximab for the treatment of MG. This report updates a previous CADTH report and in addition has a broader scope |
---|---|
Physical Description: | 1 PDF file (41 pages) illustrations |